



(51) International Patent Classification:

A61P 9/04 (2006.01) *C12N 15/861* (2006.01)
A61P 9/00 (2006.01) *A61K 48/00* (2006.01)
A61K 38/16 (2006.01)

(21) International Application Number:

PCT/US2021/044650

(22) International Filing Date:

05 August 2021 (05.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/061,342 05 August 2020 (05.08.2020) US
 63/214,119 23 June 2021 (23.06.2021) US

(71) Applicants: **ASKLEPIOS BIOPHARMACEUTICAL, INC.** [US/US]; 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **SYNPROMICS LTD** [GB/GB]; Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB). **TRETIAKOVA, Anna** [US/US]; c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US).

(72) Inventors; and

(71) Applicants: **O'CALLAGHAN, Michael W.** [US/US]; c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina

27709 (US). **ROBERTS, Michael L.** [GB/GB]; c/o Synpromics Ltd, Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB). **YANEZ-CUNA, Jorge Omar** [GB/GB]; c/o Synpromics Ltd, Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB). **IGLESIAS GONZALEZ, Juan Manuel** [GB/GB]; c/o Synpromics Ltd, Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB). **EVRIPIOTI, Antonia** [GB/GB]; c/o Synpromics Ltd, Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB). **COOPER, Sinclair** [GB/GB]; c/o Synpromics Ltd, Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB). **SETHNA, Ferzin** [US/US]; c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **HAJJAR, Roger** [US/US]; c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US).


(74) Agent: **BENN, Susanna C.** et al.; Nixon Peabody LLP, Exchange Place, 53 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

(54) Title: METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS

FIG. 7M

SP0450



(57) Abstract: The present invention relates to methods of administration of rAAV vectors in a single administration method comprising a series of sub-administrations of sub-doses of rAAV vectors. The present invention also relates to rAAV vectors comprising cardiac-specific promoters, cardiac-cell specific promoters, multi-cell cardiac specific promoters, and elements thereof. The invention also relates to rAAV vectors, pharmaceutical compositions and uses thereof in methods for treating cardiovascular disease, heart diseases and heart failure in subjects in need thereof.

[Continued on next page]

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

31 March 2022 (31.03.2022)